Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 12/20 | 0.53 |
| ▸ | ITGA4 | P13612 | 5/20 | 0.50 |
| ▸ | ITGB7 | P26010 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CNR2 | P34972 | 9/20 | 0.46 |
| ▸ | FDFT1 | P37268 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14064694 | 1.00 | CNR1 (0.53) | CNR1ITGA4ITGB7ALDH1A1CNR2 | |
| SCHEMBL4823270 | 0.96 | CNR1 (0.58) | CNR1ITGA4ITGB7ALDH1A1CNR2 | |
| Trifluoroacetic Acid SCHEMBL4831441 | 0.95 | CNR1 (0.53) | CNR1ITGA4ITGB7ALDH1A1CNR2 | |
| SCHEMBL4827955 | 0.92 | CNR1 (0.60) | CNR1ITGA4ITGB7CNR2 | |
| SCHEMBL5239744 | 0.90 | CNR1 (0.57) | CNR1ITGA4ITGB7CNR2 | |
| SCHEMBL14064714 | 0.87 | CNR1 (0.59) | CNR1CNR2 | |
| SCHEMBL4825607 | 0.87 | CNR1 (0.59) | CNR1CNR2 | |
| SCHEMBL4826924 | 0.87 | CNR1 (0.59) | CNR1CNR2 | |
| SCHEMBL4831420 | 0.86 | CNR1 (0.55) | CNR1CNR2FDFT1 | |
| SCHEMBL4825699 | 0.85 | CNR1 (0.61) | CNR1ITGA4ITGB7CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7423067-B2 | N-(3,4-diphenyl-2-butyl)cyclopentancarboxamide derivatives such as N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-3-benzoyl-cyclopentane-carboxamide; used for treating conditions including psychological disorders, eating disorders and substance abuse | MERCK & CO., INC. (US) | 2008-09-09 | — | — | US | claimed |
| US-20050239828-A1 | Spirocyclic amides as cannabinoid receptor modulators | MERCK & CO., INC. (US) | 2005-10-27 | — | — | US | claimed |
| US-7423067-B2 | N-(3,4-diphenyl-2-butyl)cyclopentancarboxamide derivatives such as N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-3-benzoyl-cyclopentane-carboxamide; used for treating conditions including psychological disorders, eating disorders and substance abuse | MERCK & CO., INC. (US) | 2008-09-09 | — | — | US | disclosed |
| US-20050239828-A1 | Spirocyclic amides as cannabinoid receptor modulators | MERCK & CO., INC. (US) | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239828-A1 | Spirocyclic amides as cannabinoid receptor modulators | CNR1, CNR2, MAG | CNR1 1/4885ITGA4 3437/4885ITGB7 3710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.